Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil-9 Immunogenicity in Well-Controlled HIV
NCT05266898Phase 4Recruiting
- Sponsor
- Louisiana State University Health Sciences Center
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Louisiana State University Health Sciences Center. Primary endpoints: Change in serological response to Gardasil-9 at 18 months, Serum antibody titers at 18 months and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05266898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05266898.